Encouraging phase 1 data for patients with ATM mutations of camonsertib plus radiations

[Maxone73]

no prostate cancer patients among the subjects but there are encouraging results

17 subjects with various solid tumors, 12 of them with a pathogenic ATM mutation, 5 with an ATM mutation of unknown effect

‘At 2-months, there were 2 complete responses (CR), 5 partial responses (PR), and 4 stable disease (SD) in the pathogenic ATM mutation group versus 1 PR and 4 SD in the VUS group.

At 6-months, in 9 evaluable patients, 2 CR, 4 PR, and 1 SD were reported in the pathogenic group versus 1 SD and 1 progressive disease (PD) in the VUS group.”

crisprmedicinenews.com/pres...

[MoonRocket]

Ok Max...if you really want to impress me, delve into the specific ATM alterations so we can see if a pattern can be discerned.

[Maxone73 in reply to MoonRocket]

Easy question ah? 😀 I am not sure they are ready to reveal that data, but if I still had unlimited access to sciencedirect I could download the full paper. I am not even sure a complete paper has been divulged, I keep finding the abstract and the results only basically. But we know which ATM alterations are considered pathogenic and which ones are unknown...

The important fact is that it looks like they were right when they supposed that ATR inhibitors would work well, even ATR + PARPi, and we will have a second generation PARPi available soon....science is coming!

DonPescado....no...sorry, got carried away for a moment! 😜